THERMOSENSITIVE HYDROGEL COLLAGENASE FORMULATIONS
It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results.
1 . A composition for treating a collagen-mediated disease, comprising collagenase and a carrier that provides sustained release of an amount of said collagenase sufficient to treat said collagen-mediated disease.
2 . The composition of claim 1 , wherein said carrier comprises gel-forming polymers.
3 . The composition of claim 2 , wherein said polymer is a triblock polymer or a copolymer based on N-siopropylacrylamide (NIPAAm)
4 . The composition of claim 3 , wherein said triblock polymers comprise poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG).
5 . The composition of claim 4 , wherein said polymers comprise a copolymer formed from PLGA and polyethylene glycol (PEG).
6 . The composition of claim 5 , wherein the PLGA and PEG copolymers are formed in repetitions of PLGA-PEG-PLGA or PEG-PLGA-PEG.
7 . The composition of claim 1 , wherein said composition is injectable, insertable or applied topically.
8 . The composition of claim 1 , which can be administered through a syringe fitted with a 28 G½ needle without pre-gelation in the needle on injection.
9 . The composition of claim 8 , wherein syringeability or compatibility has been modified by the addition to the formulation of tris (hydroxymethyl) amino methane.
10 . The composition of claim 9 , comprising tris (hydroxymethyl) amino methane in an amount sufficient to provide a pH of about 8.5.
11 . The composition of claim 3 , wherein the NIPAAm based polymer is a copolymer based on N-siopropylacrylamide (NIPAAm) and one or more of polyactide-hydroxyethyl methacrylate (HEMAPLA), acrylic acid (AAc), and methacrylated hyperbranched polyglycerol (HPG-MA).
12 . The composition of claim 11 , comprising copolymers of poly-NIPAAm and hyperbranched polyglycerols (HPG).
13 . The composition of claim 3 , having a lower critical solution temperature (LCST) of 10-37° C.
14 . The composition of claim 13 , having a LCST of approximately 25-32° C.
15 . The composition of claim 1 , wherein the composition exists as a liquid at temperatures below body temperature and as a gel at body temperature.
16 . The composition of claim 1 , wherein the collagenase is obtained from Clostridium histolyticum.
17 . The composition of claim 1 , wherein the collagenase is a mixture of collagenase I and collagenase II.
18 . A method for treating a subject suffering from a collagen-mediated disease, comprising administering to said subject the composition of claim 1 in an amount sufficient to treat said collagen-mediated disease.
19 . The method of claim 18 , wherein said disease is selected from Dupuytren's contracture, Peyronie's disease, frozen shoulder, human lipoma, canine lipoma, cellulite, uterine fibroids, chronic dermal ulcers and severely burned areas.
20 . A kit for providing at least one therapeutic dose of a formulation of claim 1 , said kit comprising in a unit package at least one container containing a sterile thermosensitive hydrogel fluid in an amount sufficient for at least one therapeutic dose; at least one second container containing an effective amount of collagenase in lyophilized, powder form: and a package insert.